公开(公告)号：JPS59172465A

公开(公告)日：1984-09-29

申请号：JP4601283

申请日：1983-03-22

申请人： Ono Pharmaceut Co Ltd

发明人： ARAI YOSHINOBU ,  WAKATSUKA HIROHISA ,  SASAKI YUUTAROU

IPC分类号： A61K31/557 ,  A61K31/5575 ,  A61P35/00 ,  A61P43/00 ,  C07C67/00 ,  C07C401/00 ,  C07C405/00

摘要： NEW MATERIAL:The compound of formula I (A is group of formula II, formula III, etc.; X is ethylene or cis-vinylene; Y is ethylene or trans-vinylene; R is H or 1W12C alkyl; R
1 is single bond or 1W5C alkylene; R
2 is 1W8C alkyl, 4W7C cycloalkyl, etc.; R
3 WR
5 are H or 1W4C alkyl; the wavy line represents that the configuration of the group attached thereto is α-, β- or their mixture).
EXAMPLE: 15-O-(3,3-Dimethyl)acryloyl-PGD
2 methyl ester.
USE: An antitumor agent exhibiting excellent antitumor activity which is not found hitherto in the conventional prostaglandin-minic compounds.
PREPARATION: The compound of formula I can be prepared by oxidizing the 9- hydroxyl group or 11-hydroxyl group of the compound of formula IV to oxo group.
COPYRIGHT: (C)1984,JPO&Japio

摘要翻译： 新材料：式Ⅰ化合物（A为式Ⅱ，式Ⅲ等基团; X为亚乙基或顺式亚乙烯基; Y为亚乙基或反式亚乙烯基; R为H或1-12C烷基; R 1为 >是单键或1-5C亚烷基; R 2是1-8C烷基，4-7C环烷基等; R 3 -R 5是H或1-4C烷基;波浪线表示 与其结合的基团的构型是α-，β-或它们的混合物）。 实施例：15-O-（3,3-二甲基）丙烯酰基-PGD 2甲酯。 用途：在常规的前列腺素 - 微型化合物中，迄今尚未发现抗肿瘤活性优异的抗肿瘤剂。 制备：式I化合物可以通过将式IV化合物的9-羟基或11-羟基氧化成氧代基来制备。

公开(公告)号：JPS61126067A

公开(公告)日：1986-06-13

申请号：JP24636284

申请日：1984-11-22

申请人： Ono Pharmaceut Co Ltd

发明人： WAKATSUKA HIROHISA ,  MIYAMOTO TSUMORU ,  ARAI YOSHINOBU

IPC分类号： C07D307/64 ,  A61K31/135 ,  A61K31/34 ,  A61K31/341 ,  A61K31/343 ,  A61K31/38 ,  A61K31/381 ,  A61K31/425 ,  A61K31/428 ,  A61K31/44 ,  A61K31/4402 ,  A61P29/00 ,  C07C67/00 ,  C07C313/00 ,  C07C323/37 ,  C07D213/70 ,  C07D277/82 ,  C07D307/82 ,  C07D333/34 ,  C07D333/62

摘要： NEW MATERIAL:A compound of formula I (R
1 , R
2 are H, allyl, 4-methoxybenzyl; R
3 is n-pentyl, formula II, formula III).
EXAMPLE: 2-Amino-4-(2-benzofuranylthio)phenol.
USE: It is used as a preventive or remedy for a variety of inflammations caused by prostaglandins and a variety of allergic inflammation caused by leucotriene.
PREPARATION: The nitro group in the compound of formula IV is selectively reduced into an amino group, e.g., in the presence of a nickel or platinum catalyst with hydrogen or with iron, zinc, titanium trichloride in benzene, with sodium sulfide in water or aqueous alcohol or hydrosulfite with aqueous ammonia to give the compound of formula I.
COPYRIGHT: (C)1986,JPO&Japio

摘要翻译： 新材料：式I化合物（R 1，R 2）为H，烯丙基，4-甲氧基苄基; R 3为正戊基，式II，式III）。 实施例：2-氨基-4-（2-苯并呋喃硫基）苯酚。 用途：用于预防或治疗由前列腺素引起的各种炎症和由白三烯引起的各种过敏性炎症。 制备：将式Ⅳ化合物中的硝基选择性还原为氨基，例如在镍或铂催化剂存在下，与氢或铁，锌，三氯化钛在苯中，与硫化钠在水或水溶液 醇或连二亚硫酸盐与氨水反应得到式I化合物。

公开(公告)号：JPS59164770A

公开(公告)日：1984-09-17

申请号：JP3817283

申请日：1983-03-10

申请人： Ono Pharmaceut Co Ltd

发明人： ARAI YOSHINOBU ,  WAKATSUKA HIROHISA ,  SASAKI YUUTAROU

IPC分类号： C07D309/12 ,  A61K31/557 ,  A61K31/5575 ,  A61P35/00 ,  A61P43/00 ,  C07C49/743 ,  C07C49/753 ,  C07C67/00 ,  C07C69/025 ,  C07C69/533 ,  C07C271/12 ,  C07C401/00 ,  C07C405/00

摘要： NEW MATERIAL:A prostaglandin (PG for short) D analog compound shown by the formula I {[A] is group shown by the formula II, III (double bond between C
9 -C
10 is Z, etc.; X is ethylene, or cis-vinylene; C
13 -C
14 -C
15 is group shown by the formula IV (double bond in C
13 -C
14 is E), etc.; R is -CO-CR
3 =CR
4 R
5 (R
3 , R
4 , and R
5 are H, or 1W4C alkyl), etc.; R
1 is single bond, or 1W5C alkylene; R
2 is 1W8C alkyl, etc.}, or its cyclodextrin inclusion compound.
EXAMPLE: 1-O-(3,3-Dimethylacryloyl)-PGD
2 alcohol.
USE: A strong antitumor agent, having extremely low toxicity.
PREPARATION: For example, a compound shown by the formula V (R
b is H, etc.) is reacted using an aqueous solution of an acid such as HCl, etc. in an inert organic solvent such as methylene chloride, etc. at the reflux temperature of the solvent, to prepared the compound shown by the formula I (with the proviso that R=R
b ).
COPYRIGHT: (C)1984,JPO&Japio

摘要翻译： 新材料：由式I {[A]表示的前列腺素（简称PG）D类似物化合物是式II，III所示的基团（C 9 -C 10之间的双键为Z等; X为亚乙基或顺式 - 亚乙烯基; C13-C14-C15为式IV所示的基团（C13-C14中的双键为E）等; R为-CO-CR 3 = CR 4 R 5（R' R 3，R 4和R 5是H或1-4C烷基）等; R 1是单键或1-5C亚烷基; R 2是1-8C烷基， 实施例：1-O-（3,3-二甲基丙烯酰）-PGD2醇使用：毒性极低的强抗肿瘤剂制备例如，式 在惰性有机溶剂如二氯甲烷等中，使用酸如HCl等的水溶液在溶剂的回流温度下使V（R b等于H等）反应，制备 化合物如式I所示（条件是R = R）。

公开(公告)号：JPS59164769A

公开(公告)日：1984-09-17

申请号：JP3817183

申请日：1983-03-10

申请人： Ono Pharmaceut Co Ltd

发明人： ARAI YOSHINOBU ,  WAKATSUKA HIROHISA ,  SASAKI YUUTAROU

IPC分类号： C07D309/12 ,  A61K31/557 ,  A61K31/5575 ,  A61P35/00 ,  A61P43/00 ,  C07C49/743 ,  C07C67/00 ,  C07C401/00 ,  C07C405/00

摘要： NEW MATERIAL:A prostaglandin (PG for short) D analog compound shown by the formula I {[A] is group shown by the formula II or III (with the proviso that double bond between C
9 -C
10 is Z); R
1 is 1W8C alkyl; double bond between C
5 -C
6 is Z; double bond between C
13 -C
14 is E} or its cyclodextrin inclusion compound.
EXAMPLE: PGD
2 alcohol.
USE: A strong antitumor agent, having extremely low toxicity.
PREPARATION: A compound shown by the formula IV [R
2 is (one alkyl-substituted tetrahydropyran-2-yl, tetrahydrofuran-2-yl, or 1-ethoxyethyl] or a compound shown by the formula V is hydrolyzed under an acidic conditions using acetic acid so that OR
2 at 1-, 9- and 15-positions, or 1- and 15-positions are converted into OH, to give the desired conpound shown by the formula I .
COPYRIGHT: (C)1984,JPO&Japio

摘要翻译： 新材料：由式I {[A]表示的前列腺素（简称为PG）D类似化合物是式II或III所示的基团（条件是C9-C10之间的双键为Z）; R 1是1-8C烷基; C5-C6之间的双键为Z; C13-C14之间的双键为E}或其环糊精包合物。 实施例：PGD2醇。 用途：强力抗肿瘤药物，毒性极低。 制备：由式IV表示的化合物[R 2]是（一个烷基取代的四氢吡喃-2-基，四氢呋喃-2-基或1-乙氧基乙基）或式V所示的化合物在酸性 使用乙酸的条件使得1-，9-和15-位或1-和15-位的OR 2转化为OH，得到式I所示的所需结构。

公开(公告)号：JPS59181253A

公开(公告)日：1984-10-15

申请号：JP5244983

申请日：1983-03-30

申请人： Ono Pharmaceut Co Ltd

发明人： ARAI YOSHINOBU ,  WAKATSUKA HIROHISA ,  SASAKI YUUTAROU

IPC分类号： A61K31/557 ,  A61K31/5575 ,  A61P35/00 ,  A61P43/00 ,  C07C67/00 ,  C07C401/00 ,  C07C405/00

摘要： NEW MATERIAL:A compound shown by the formula I [pG
1 and pG
2 are group shown by the formula II, formula III, or formula IV (X
1 WX
3 are ethylene, cis- vinylene; R
1a , R
1b , and R
1c are single bond, or 1W5C alkylene; R
2a , R
2b , and R
2c are 1W8C alkyl, etc.; double bond between 9W10C is Z; double bond between 13W14C is E, Z, etc.); Y
1 and Y
2 are O, imino, etc.; n is 2W8].
USE: An antitumor agent. Having low toxicity and extremely improved antitumor action, for example, useful for leukemia, solid cancers, etc.
PREPARATION: A compound show on by the formula V is reacted with a compound shown by the formula VI in an inert organic solvent in the presence of a base such as triethylamine, pyridine, etc. at 0°C W room temperature to give a compound shown by the formula I .
COPYRIGHT: (C)1984,JPO&Japio

摘要翻译： 新物质：由式I [pG 1和pG 2]表示的化合物是式II，式III或式IV所示的基团（X 1 -X -X 3）是亚乙基，顺式 - 亚乙烯基 R 1a，R 1b和R 1c是单键或1-5C亚烷基; R 2a，R 2b和R 2c是1-8C烷基等; 9-10C之间的双键为Z; 13-14C之间的双键为E，Z等）; Y 1和Y 2都是O，亚氨基等; n为2-8]。 用途：抗肿瘤剂。 具有低毒性和极其改善的抗肿瘤作用，例如可用于白血病，固体癌症等。制备：将式V化合物与式VI所示的化合物在惰性有机溶剂中，在存在 碱如三乙胺，吡啶等在室温下反应，得到式I化合物。

公开(公告)号：JPS595154A

公开(公告)日：1984-01-12

申请号：JP11275682

申请日：1982-06-30

申请人： Ono Pharmaceut Co Ltd

发明人： WAKATSUKA HIROHISA ,  YAMATO TAKASHI ,  HASHIMOTO SHINSUKE

IPC分类号： A61K31/557 ,  A61K31/5575 ,  A61P35/00 ,  A61P43/00 ,  C07C67/00 ,  C07C401/00 ,  C07C405/00 ,  C08B37/00

CPC分类号： C08B37/0015 ,  C07C405/00 ,  C07C405/0033 ,  Y10S514/908

摘要： NEW MATERIAL:The compound of formula I ([A] is group of formula II W formula IV; X is ethylene or cis-vinylene; when [A] is group of formula II or formula III, C
13 -C
14 -C
15 is group of formula V, and when [A] is group of formula IV, it is group of formula VI; R is H or 1W12C straight or branched chain alkyl; R
1 is single bond, or 1W5C straight or branched chain alkylene; R
2 is 1W 8C straight or branched chain alkyl, etc.; the configuration of C
9 -C
10 in group of formula III and formula IV is Z; that of C
13 -C
14 in group of formula V is E; those of C
12 -C
13 and C
14 -C
15 in group of formula VI are E, Z or EZ; when R
1 is single bond, R
2 is not substituted or unsubstituted phenoxy), its cyclodextrin- clathrate compound, or when R=H, its salt.
EXAMPLE: Trans-Δ
2 -PGD
2 .
USE: Antitumor agent.
PROCESS: A compound of formula I wherein [A] is group of formula II can be prepared by hydrolyzing the compound of formula VII (R
3 is 1-ethoxyethyl, etc.) under acidic condition, and if necessary, esterifying the resultant compound.
COPYRIGHT: (C)1984,JPO&Japio

摘要翻译： 新物质：式I化合物（[A]是式Ⅱ-式Ⅳ基团; X是亚乙基或顺式亚乙烯基;当[A]为式Ⅱ或式Ⅲ基团时，C13-C14-C15为 式Ⅴ，当[A]为式Ⅳ基团时，其为式Ⅵ基团; R为H或1-12C直链或支链烷基; R 1为单键或1-5C直链或支链 亚烷基; R 2为1-8直链或支链烷基等;式III和式IV组中的C 9 -C 10的构型为Z;式V中C 13 -C 14的构型为E; 式VI中的C 12 -C 13和C 14 -C 15是E，Z或EZ;当R 1是单键时，R 2不是取代或未取代的苯氧基），其环糊精包合物，或当R = H，其盐。 实施例：反式DELTA <2> -PGD 2。 用途：抗肿瘤剂。 方法：其中[A]为式II基团的式I化合物可以通过在酸性条件下水解式VII化合物（R 3为1-乙氧基乙基等），如果需要，将所得物 复合。

公开(公告)号：JPS59190964A

公开(公告)日：1984-10-29

申请号：JP6573983

申请日：1983-04-15

申请人： Ono Pharmaceut Co Ltd

发明人： ARAI YOSHINOBU ,  WAKATSUKA HIROHISA ,  SASAKI YUUTAROU

IPC分类号： C08B37/16 ,  A61K31/557 ,  A61K31/5575 ,  A61P35/00 ,  A61P43/00 ,  C07C49/647 ,  C07C49/687 ,  C07C49/743 ,  C07C49/753 ,  C07C67/00 ,  C07C401/00 ,  C07C405/00

摘要： NEW MATERIAL:A compound expressed by formula I (A is expressed by formulas II, III or IV; X is ethylene or cis-vinylene; the bonds between the carbon atoms at the 13-, 14- and 15-positions are expressed by formula V when A is expressed by formula IIor III, and formula VI when A is expressed by formula IV; R is 1W12C straight chain or branched chain alkyl; R
1 is single bond, 1W5C straight chain or branched chain alkylene; R
2 is 1W8C straight chain or branched chain alkyl; etc.; the double bond between the carbon atoms at the 9- and 10-positions in formulas III and IV is Z; the double bond between carbon atoms at the 13- and 14-positions in formula V is E; the double bond between carbon atoms the 12- and 13-positions and the double bond between carbon atoms at the 14- and 15-positions in formula VI are E, Z or a mixture thereof) or a cyclodextrin clathrate compound thereof.
EXAMPLE: 2-Decarboxy-2-methyl-PGD
2 .
USE: An antitumor agent having almost no pharmacological action unique to prostaglandin.
PREPARATION: Compounds expressed by formulas VII and VIII (R
3 is tetrahydropyran-2-yl, etc.) are hydrolyzed under acidic conditions to give the compound expressed by formula I (A is expressed by formula II or III).
COPYRIGHT: (C)1984,JPO&Japio

摘要翻译： 新材料：由式I表示的化合物（A由式II，III或IV表示; X是亚乙基或顺式 - 亚乙烯基; 13,14和15位的碳原子之间的键由式 当A由式IV表示时，A表示为A，而式Ⅳ表示为A，R为1-12C直链或支链烷基; R 1为单键，1-5C直链或支链亚烷基 R 2是1-8C直链或支链烷基等;式Ⅲ和Ⅳ中9位和10位的碳原子之间的双键是Z;碳原子之间的双键在 式V中的13位和14位为E;式VI中碳原子之间的双键和第十六位和第十六位的碳原子之间的双键为E，Z或混合物 ）或其环糊精包合物化合物。 实施例：2-脱羧-2-甲基PGD 2。 用途：几乎没有前列腺素特有的药理作用的抗肿瘤剂。 制备：由式VII和VIII表示的化合物（R 3是四氢吡喃-2-基等）在酸性条件下水解，得到由式I表示的化合物（A由式II或III表示）。

公开(公告)号：JPS59190963A

公开(公告)日：1984-10-29

申请号：JP6573883

申请日：1983-04-15

申请人： Ono Pharmaceut Co Ltd

发明人： ARAI YOSHINOBU ,  WAKATSUKA HIROHISA ,  SASAKI YUUTAROU

IPC分类号： C08B37/16 ,  A61K31/557 ,  A61K31/5575 ,  A61P35/00 ,  A61P43/00 ,  C07C67/00 ,  C07C401/00 ,  C07C405/00

摘要： NEW MATERIAL:A compound expressed by formula I [A is formula II, III or IV (the broken line represents α-configuaconfiguration; symbol represents β-configuration; the wavy line represents α-, β-configuration or a mixture thereof; the bond between carbon atoms at the 12- and 13- positions and the bond between carbon atoms at the 14- and 15-positions informula II are respectively trans- or cis-configuration or a mixture thereof; the bond between carbon atoms at the 9- 10-positions in formula II is cis-configuration; the bond between carbon atoms at the 9- and 10-positions and the bond between carbon atoms at the 13- and 14-positions in formula IIIare respectively cis- or trans-configuration or mixture thereof; the bond between carbon atoms at the 13- and 14-positions in formula IV is trans-configuration); X is ethylene, etc.; R
1 is H or 1W4C alkyl; R
2 is 2W6C alkyl substituted by 1W3 OH groups; R
3 is single bond or 1W5C alkylene; R
4 is 1W8C alkyl, etc.] or a cyclodextrin clathrate compound thereof.
USE: An antitumor agent having almost no pharmacological action unique to prostaglandin.
PREPARATION: A compound expressed by formula V (R
5 is 1-ethoxyethyl, etc.) is hydrolyzed under acidic conditions to give a compound expressed by formula I (A is expressed by formula III) or a compound expressed by formula VI is hydrolyzed under acidic conditions to afford the compound expressed by the formula I (A is expressed by formula IV).
COPYRIGHT: (C)1984,JPO&Japio

摘要翻译： 新材料：由式I表示的化合物[A为式II，III或IV（虚线表示α构型;符号表示β构型;波浪线表示α，β构型或其混合物;键 在12位和13位的碳原子之间以及14位和15位信号II的碳原子之间的键分别是反式或顺式构型或其混合物;碳原子之间的键在9- 10 式II中的 - 位置是顺式构型;在式III中的9-和10-位的碳原子之间的键和在13和14位的碳原子之间的键分别是顺式或反式构型或其混合物 式IV中13位和14位的碳原子之间的键是反式构型）; X是乙烯等; R 1是H或1-4C烷基; R 2是被1-3个OH基取代的2-6C烷基; R 3是单键或1-5C亚烷基; R 4是1-8C烷基等]或其环糊精包合物。 用途：几乎没有前列腺素特有的药理作用的抗肿瘤剂。 制备：由式V表示的化合物（R 5为1-乙氧基乙基等）在酸性条件下水解，得到由式I表示的化合物（A由式III表示）或式VI表示的化合物为 在酸性条件下水解，得到由式I表示的化合物（A由式IV表示）。

公开(公告)号：JPS595155A

公开(公告)日：1984-01-12

申请号：JP11275782

申请日：1982-06-30

申请人： Ono Pharmaceut Co Ltd

发明人： WAKATSUKA HIROHISA ,  YAMATO TAKASHI ,  HASHIMOTO SHINSUKE

IPC分类号： A61K31/557 ,  A61K31/5575 ,  A61P35/00 ,  A61P43/00 ,  C07C67/00 ,  C07C401/00 ,  C07C405/00 ,  C07D307/937 ,  C08B37/00

CPC分类号： C07D307/937 ,  C07C405/00 ,  C08B37/0015

摘要： NEW MATERIAL:The compound of formula I ([A] is group of formula II W formula IV; when [A] is group of formula II, C
13 -C
14 -C
15 is group of formula V, and when [A] is group of formula III or formula IV, it is group of formula VI; R is H or 1W12C alkyl; R
1 is single bond or 1W5C alkylene; R
2 is 1W8C alkyl, etc.; the configuration of C
9 -C
10 in group of formula IV is Z, that of C
13 - C
14 in group of formula V is E and those of C
12 -C
13 and C
14 -C
15 are E, Z or EZ; when R
1 is single bond, R
2 is not substituted or unsubstituted phenoxy), its cyclodextrin-clathrate compound, or when R=H, its salt.
EXAMPLE: 6-Keto-PGD
1 methyl ester.
USE: An antitumor agent.
PROCESS: A compound of formula I wherein [A] is group of formula II or formula III can be prepared by hydrolyzing the compound of formula VII (R
3 is 1- ethoxyethyl, etc.; R
4 is lower alkyl) under acidic condition. The product wherein [A] is group of formula II can be converted to anothr compound of formula I wherein [A] is group of formula IV by reacting in an aqueous solution of an acid.
COPYRIGHT: (C)1984,JPO&Japio

摘要翻译： 新物质：式I化合物（[A]是式Ⅱ-式IV的基团;当[A]为式II基团时，C13-C14-C15为式V基团，当[A]为 式III或式IV，它是式VI的基团; R是H或1-12C烷基; R 1是单键或1-5C亚烷基; R 2是1-8C烷基等;配置 式Ⅴ基团中的C 9 -C 10的化合物是Z，式Ⅴ中C 13 -C 14的化合物是E，C 12 -C 13和C 14 -C 15的那些是E，Z或EZ;当R 1是单键时， R 2不是取代或未取代的苯氧基），其环糊精包合物，或当R = H时，其盐。 实施例：6-酮-PGD1甲酯。 用途：抗肿瘤剂。 方法：其中[A]是式II或式III基团的式I化合物可以通过水解式VII化合物（R 3是1-乙氧基乙基等; R 4是低级烷基）来制备， 在酸性条件下。 其中[A]是式II基团的产物可以通过在酸的水溶液中反应而转化为式I化合物，其中[A]是式IV基团。

公开(公告)号：JPS591463A

公开(公告)日：1984-01-06

申请号：JP10980682

申请日：1982-06-28

申请人： Ono Pharmaceut Co Ltd

发明人： WAKATSUKA HIROHISA ,  YAMATO TAKASHI ,  HASHIMOTO SHINSUKE

IPC分类号： A61K31/557 ,  A61K31/5575 ,  A61P35/00 ,  A61P43/00 ,  C07C67/00 ,  C07C401/00 ,  C07C405/00 ,  C08B37/00

CPC分类号： C08B37/0015 ,  C07C405/00 ,  C07C405/0016 ,  C07C405/0025 ,  C07C405/0041

摘要： NEW MATERIAL:A compound of formula I ([A] is formula IIWformula IV; X is ethylene, cis-vinylene; C
13 -C
14 -C
15 is formula V, when [A] is formula II or III, or is COCH
2 OH, -CONHSO
2 R
5 (R
5 is 1W4C alkyl), when [A] is formula III or IV; R
1 is single bond; R
2 is 1W8C alkylene; the double bond between C
9 and C
10 is Z; between C
13 and C
14 , E; between C
14 and C
15 , E or Z; where, when R
1 is a single bond, R
2 is not phenoxy).
EXAMPLE: 2-Decarboxy-2-glycoloyl-PGD
20 .
USE: Antitumor agent.
PREPARATION: A compound of formula VII (R
3 , R
4 are 1W4C alkyl; R
6 is tetrahydropyran-2-yl) is hydrolyzed under acidic conditions to give a compound of formula I where [A] is formula II.
COPYRIGHT: (C)1984,JPO&Japio

摘要翻译： 新物质：式I化合物（[A]为式Ⅱ式IV; X为亚乙基，顺式亚乙烯基; C 13 -C 14 -C 15为式V，当[A]为式II或III或COCH 2 OH时， -CONHSO 2 R 5（R 5为1-4 C烷基），当[A]为式III或IV时，R 1为单键; R 2为1-8C亚烷基; C 9上的双键 C 13和C 14之间，E; C 14和C 15，E或Z之间;当R 1是单键时，R 2不是苯氧基）。 实施例：2-脱羧-2-乙醇酰 - PGD20。 用途：抗肿瘤剂。 制备：式Ⅰ化合物（R 3，R 4为1-4C烷基; R 6为四氢吡喃-2-基）在酸性条件下水解，得到式Ⅰ化合物，其中[A] 是公式II。